Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Neurogenetics
Published in: neurogenetics 1/2011

Open Access 01-02-2011 | SHORT COMMUNICATION

OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users

Authors: Matthijs L. Becker, Loes E. Visser, Ron H. N. van Schaik, Albert Hofman, André G. Uitterlinden, Bruno H. Ch. Stricker

Published in: Neurogenetics | Issue 1/2011

Login to get access

Abstract

Substrates for the Organic Cation Transporter 1, encoded by the SLC22A1 gene, are metformin, amantadine, pramipexole, and, possibly, levodopa. Recently, we identified that the rs622342 A > C polymorphism is associated with the HbA1c lowering effect in metformin users. In the Rotterdam Study, we associated this polymorphism with higher prescribed doses of all anti-Parkinsonian drugs. Between the first and fifth prescriptions for levodopa, for each minor rs622342 C allele, the prescribed doses were 0.34 defined daily dose higher (95% CI 0.064, 0.62; p = 0.017). The mortality ratio after start of levodopa therapy was 1.47 times higher (95% CI 1.01, 2.13; p = 0.045).
Literature
1.
Koepsell H, Lips K, Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24:1227–1251CrossRefPubMed
2.
Jonker JW, Schinkel AH (2004) Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 308:2–9CrossRefPubMed
3.
Breidert T, Spitzenberger F, Grundemann D, Schomig E (1998) Catecholamine transport by the organic cation transporter type 1 (OCT1). Br J Pharmacol 125:218–224CrossRefPubMed
4.
Okura T, Ito R, Ishiguro N, Tamai I, Deguchi Y (2007) Blood-brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci 80:1564–1571CrossRefPubMed
5.
Ishiguro N, Saito A, Yokoyama K, Morikawa M, Igarashi T, Tamai I (2005) Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos 33:495–499CrossRefPubMed
6.
Goralski KB, Lou G, Prowse MT, Gorboulev V, Volk C, Koepsell H, Sitar DS (2002) The cation transporters rOCT1 and rOCT2 interact with bicarbonate but play only a minor role for amantadine uptake into rat renal proximal tubules. J Pharmacol Exp Ther 303:959–968CrossRefPubMed
7.
Gomes P, Serrao MP, Viera-Coelho MA, Soares-da-Silva P (1997) Opossum kidney cells take up L-DOPA through an organic cation potential-dependent and proton-independent transporter. Cell Biol Int 21:249–255CrossRefPubMed
8.
Pinto-do OP, Soares-da-Silva P (1996) Studies on the pharmacology of the inward transport of L-DOPA in rat renal tubules. Br J Pharmacol 118:741–747
9.
Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH (2009) Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 9:242–247CrossRefPubMed
10.
Hofman A, Breteler MM, van Duijn CM, Janssen HL, Krestin GP, Kuipers EJ, Stricker BH, Tiemeier H, Uitterlinden AG, Vingerling JR, Witteman JC (2009) The Rotterdam Study: 2010 objectives and design update. Eur J Epidemiol 24:553–572CrossRefPubMed
11.
International HapMap Consortium (2003) The International HapMap Project. Nature 426:789–796CrossRef
12.
Martel F, Grundemann D, Calhau C, Schomig E (2001) Apical uptake of organic cations by human intestinal Caco-2 cells: putative involvement of ASF transporters. Naunyn Schmiedebergs Arch Pharmacol 363:40–49CrossRefPubMed
Metadata
Title
OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users
Authors
Matthijs L. Becker
Loes E. Visser
Ron H. N. van Schaik
Albert Hofman
André G. Uitterlinden
Bruno H. Ch. Stricker
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
Neurogenetics / Issue 1/2011
Print ISSN: 1364-6745
Electronic ISSN: 1364-6753
DOI
https://doi.org/10.1007/s10048-010-0254-5

Other articles of this Issue 1/2011

neurogenetics 1/2011 Go to the issue

LETTER TO THE EDITORS

Confirmed association between monoamine oxidase A molecular polymorphisms and Sudden Infant Death Syndrome

Original Article

Progressive cavitating leukoencephalopathy associated with respiratory chain complex I deficiency and a novel mutation in NDUFS1

ORIGINAL ARTICLE

Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability

ORIGINAL ARTICLE

A whole-genome scan in a large family with leukodystrophy and oligodontia reveals linkage to 10q22

ORIGINAL ARTICLE

Hydroxyurea enhances SMN2 gene expression through nitric oxide release

ORIGINAL ARTICLE

Partial SPAST and DPY30 deletions in a Japanese spastic paraplegia type 4 family